Zymeworks Inc. (ZYME)
USD 11.49
(2.13%)
USD 11.49
(2.13%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -130.83 Million USD | 64.9% |
| 2022 | -372.79 Million USD | -119.9% |
| 2021 | -169.53 Million CAD | 27.36% |
| 2020 | -233.39 Million USD | -92.05% |
| 2019 | -121.52 Million USD | -188.33% |
| 2018 | -42.14 Million USD | -17.46% |
| 2017 | -35.88 Million USD | -198.73% |
| 2016 | -12.01 Million USD | -4.33% |
| 2015 | -11.51 Million USD | 75.42% |
| 2014 | -46.83 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -89.59 Million USD | 31.52% |
| 2024 Q2 | -50.89 Million USD | 43.19% |
| 2024 Q3 | -102.13 Billion USD | -100.61% |
| 2023 Q1 | -154.24 Million USD | 58.63% |
| 2023 FY | -130.83 Million USD | 64.9% |
| 2023 Q4 | -130.83 Million USD | -92.17% |
| 2023 Q3 | -68.08 Million USD | 40.72% |
| 2023 Q2 | -114.84 Million USD | 25.54% |
| 2022 Q4 | -372.79 Million USD | -464.95% |
| 2022 FY | -372.79 Million USD | -119.9% |
| 2022 Q3 | -65.98 Million USD | 60.4% |
| 2022 Q1 | -243.67 Million USD | -43.73% |
| 2022 Q2 | -166.64 Million USD | 31.61% |
| 2021 FY | -169.53 Million CAD | 27.36% |
| 2021 Q4 | -169.53 Million CAD | 24.06% |
| 2021 Q3 | -223.24 Million USD | 0.92% |
| 2021 Q1 | -271.52 Million USD | -16.34% |
| 2021 Q2 | -225.31 Million USD | 17.02% |
| 2020 Q2 | -210.99 Million USD | -16.97% |
| 2020 Q4 | -233.39 Million USD | 1.16% |
| 2020 Q1 | -180.37 Million USD | -48.43% |
| 2020 Q3 | -236.13 Million USD | -11.92% |
| 2020 FY | -233.39 Million USD | -92.05% |
| 2019 Q4 | -121.52 Million USD | 50.2% |
| 2019 Q3 | -244.03 Million USD | 11.46% |
| 2019 Q2 | -275.63 Million USD | -686.17% |
| 2019 Q1 | -35.06 Million USD | 16.82% |
| 2019 FY | -121.52 Million USD | -188.33% |
| 2018 Q1 | -30.91 Million USD | 13.85% |
| 2018 Q2 | -55.31 Million USD | -78.93% |
| 2018 Q3 | -28.31 Million USD | 48.81% |
| 2018 Q4 | -42.14 Million USD | -48.86% |
| 2018 FY | -42.14 Million USD | -17.46% |
| 2017 FY | -35.88 Million USD | -198.73% |
| 2017 Q4 | -35.88 Million USD | -191.22% |
| 2017 Q3 | -12.32 Million USD | 52.59% |
| 2017 Q2 | -25.99 Million USD | -338.96% |
| 2017 Q1 | -5.92 Million USD | 50.71% |
| 2016 Q3 | -24.21 Million USD | 0.0% |
| 2016 Q1 | 15.16 Million USD | 231.61% |
| 2016 Q4 | -12.01 Million USD | 50.39% |
| 2016 FY | -12.01 Million USD | -4.33% |
| 2015 Q4 | -11.51 Million USD | 0.0% |
| 2015 FY | -11.51 Million USD | 75.42% |
| 2014 FY | -46.83 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ADC Therapeutics SA | -154.22 Million USD | 15.164% |
| Alto Neuroscience, Inc. | 68.91 Million USD | 289.85% |
| Annovis Bio, Inc. | -5.75 Million USD | -2173.525% |
| Biohaven Pharmaceutical Holding Company Ltd. | -218.84 Million USD | 40.215% |
| Ginkgo Bioworks Holdings, Inc. | -707.09 Million USD | 81.497% |
| Nuvation Bio Inc. | -38.64 Million USD | -238.582% |
| Nuvation Bio Inc. | -38.64 Million USD | -238.582% |
| Arcus Biosciences, Inc. | -116 Million USD | -12.789% |